ROCKVILLE, Md., Oct. 16 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that Kenneth W. Bair, Ph.D. has been appointed its Senior Vice President, Research and Development. Dr. Bair has also been elected an executive officer of EntreMed by the Board of Directors, reporting to James S. Burns, President & CEO.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )
Dr. Bair brings to EntreMed over 25 years of management experience in oncology drug discovery, development and chemistry. Prior to joining EntreMed, Dr. Bair served as Senior Vice President and Head, BioPharmaceuticals Research at Chiron Corporation in Emeryville, California. Prior to joining Chiron Corporation in 2003, Dr. Bair was Vice President, Discovery Oncology at Pharmacia Corporation in Peapack, New Jersey. From 1982 until joining Pharmacia, Dr. Bair held positions of increasing responsibility within the pharmaceutical industry, including Unit Head of Oncology at Novartis Pharmaceuticals Corporation and Executive Director and Head, Oncology Research Program, Sandoz Pharmaceuticals Corporation; and various oncology research positions at Burroughs Wellcome, Research Triangle Park, North Carolina. Dr. Bair received his Ph.D. in organic chemistry from Brandeis University, Waltham, Massachusetts, and was a Postdoctoral Fellow at the Massachusetts Institute of Technology, Cambridge, Massachusetts.
Dr. Bair commented on his appointment at EntreMed, “I am delighted to be joining the EntreMed team. The Company has extensive scientific expertise in angiogenesis, cell cycle regulation, kinase inhibition and inflammation, which provide a strong foundation for building a leading oncology franchise. EntreMed’s pipeline of HIF-1 alpha and kinase inhibitors fit well with my background and research interests. I look forward to leading the advancement of EntreMed’s mechanism-based drugs for the treatment of cancer and inflammatory diseases.”
James S. Burns, EntreMed President & CEO commented, “I am very pleased to welcome Ken to EntreMed’s leadership team. Ken joins EntreMed with a strong oncology research and development background in large pharmaceutical and biotech companies, experience that will be instrumental in leading EntreMed into its next phase of development.”
Mr. Burns continued, “Ken has a solid track record in identifying and developing oncology compounds. As Senior Vice President of Research and Development, Ken will play a critical role in leading the development of our ongoing research programs, prioritizing the existing portfolio, and identifying new compounds for our pipeline in order to select the best programs based on the strength of the data and their prospective competitive position.”
About EntreMed
EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) NCD (2-methoxyestradiol or 2ME2) is currently in multiple Phase 2 clinical trials for cancer. MKC-1, an oral cell-cycle regulator, is in multiple Phase 1 and 2 studies for cancer. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. Panzem(R) is also in preclinical development for rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, is in preclinical development for cancer. EntreMed’s goal is to develop and commercialize new compounds based on the Company’s expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company’s web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.
Forward Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under “Risk Factors,” including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company’s product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company’s proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).
CONTACT: Ginny Dunn, Associate Director, Corporate Communications &
Investor Relations of EntreMed, Inc., +1-240-864-2643
Web site: http://www.entremed.com/
